Katherine J P Schwenger1,2, Sandra E Fischer2,3, Timothy D Jackson4,5, Allan Okrainec1,4,5, Johane P Allard6,7,8. 1. Institute of Medical Science, University of Toronto, Toronto, ON, Canada. 2. Toronto General Hospital, University Health Network, 585 University Avenue, 9-973, Toronto, ON, M5G 2C4, Canada. 3. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 4. Division of General Surgery, University of Toronto, Toronto, ON, Canada. 5. Division of General Surgery|, University Health Network, Toronto, ON, Canada. 6. Toronto General Hospital, University Health Network, 585 University Avenue, 9-973, Toronto, ON, M5G 2C4, Canada. dr.johane.allard@uhn.ca. 7. Department of Medicine, University of Toronto, Toronto, ON, Canada. dr.johane.allard@uhn.ca. 8. Department of Nutritional Sciences, University of Toronto, Toronto, ON, Canada. dr.johane.allard@uhn.ca.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) affects 75 to 100% of the patients undergoing bariatric surgery (BSx), with non-alcoholic steatohepatitis (NASH) being present in 24 to 98% of the patients. We do not know whether these rates were before or after a very low calorie diet (VLCD) often prescribed before laparoscopic BSx and what is the prevalence of NAFLD post-VLCD. PURPOSE: The purpose of this study is to determine the prevalence of simple steatosis (SS) and NASH in obese individuals undergoing BSx post-VLCD and assess biochemical markers pre- and post-VLCD in a subgroup of patients. METHODS: One hundred and thirty-nine patients undergoing BSx at a single Canadian bariatric program had biochemical and clinical variables collected pre-VLCD. In 21 patients, biochemical measurements were repeated post-VLCD. During BSx, a wedged liver biopsy was performed in all patients and histology was reported as normal liver (NL), SS, or NASH. RESULTS: NAFLD was diagnosed in 76.3% of the BSx patients with 61.9% having SS and 14.4% having NASH; 23.7% had NL. Those with NASH had significantly higher (p < 0.05) pre-VLCD ALT, AST, insulin resistance, and proportion of individuals with diabetes compared to those with NL. Overall, VLCD resulted in significant decreases in BMI, ALP, fasting glucose and insulin, HbA1c, total cholesterol, HDL and LDL cholesterol, and significant increases in AST and ALT. Changes were similar between groups. CONCLUSIONS: Post-VLCD, the prevalence of NAFLD and NASH was lower compared to published reports, with almost 25% of the patients having a NL. With VLCD, metabolic and clinical changes were similar between the three groups suggesting that pre-VLCD factors may affect liver histology.
BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) affects 75 to 100% of the patients undergoing bariatric surgery (BSx), with non-alcoholic steatohepatitis (NASH) being present in 24 to 98% of the patients. We do not know whether these rates were before or after a very low calorie diet (VLCD) often prescribed before laparoscopic BSx and what is the prevalence of NAFLD post-VLCD. PURPOSE: The purpose of this study is to determine the prevalence of simple steatosis (SS) and NASH in obese individuals undergoing BSx post-VLCD and assess biochemical markers pre- and post-VLCD in a subgroup of patients. METHODS: One hundred and thirty-nine patients undergoing BSx at a single Canadian bariatric program had biochemical and clinical variables collected pre-VLCD. In 21 patients, biochemical measurements were repeated post-VLCD. During BSx, a wedged liver biopsy was performed in all patients and histology was reported as normal liver (NL), SS, or NASH. RESULTS: NAFLD was diagnosed in 76.3% of the BSxpatients with 61.9% having SS and 14.4% having NASH; 23.7% had NL. Those with NASH had significantly higher (p < 0.05) pre-VLCD ALT, AST, insulin resistance, and proportion of individuals with diabetes compared to those with NL. Overall, VLCD resulted in significant decreases in BMI, ALP, fasting glucose and insulin, HbA1c, total cholesterol, HDL and LDL cholesterol, and significant increases in AST and ALT. Changes were similar between groups. CONCLUSIONS: Post-VLCD, the prevalence of NAFLD and NASH was lower compared to published reports, with almost 25% of the patients having a NL. With VLCD, metabolic and clinical changes were similar between the three groups suggesting that pre-VLCD factors may affect liver histology.
Authors: Stephen Hewitt; Sjur Humerfelt; Torgeir T Søvik; Erlend T Aasheim; Hilde Risstad; Jon Kristinsson; Tom Mala Journal: Obes Surg Date: 2014-05 Impact factor: 4.129
Authors: Gary D Wu; Jun Chen; Christian Hoffmann; Kyle Bittinger; Ying-Yu Chen; Sue A Keilbaugh; Meenakshi Bewtra; Dan Knights; William A Walters; Rob Knight; Rohini Sinha; Erin Gilroy; Kernika Gupta; Robert Baldassano; Lisa Nessel; Hongzhe Li; Frederic D Bushman; James D Lewis Journal: Science Date: 2011-09-01 Impact factor: 47.728
Authors: Mohammad Reza Ghadir; Ali Akbar Riahin; Abbas Havaspour; Mehrdad Nooranipour; Abbas Ali Habibinejad Journal: Hepat Mon Date: 2010-12-01 Impact factor: 0.660
Authors: Ajay Kumar Jain; Carel W le Roux; Puneet Puri; Ali Tavakkoli; Nana Gletsu-Miller; Blandine Laferrère; Richard Kellermayer; John K DiBaise; Robert G Martindale; Bruce M Wolfe Journal: JPEN J Parenter Enteral Nutr Date: 2018-02 Impact factor: 4.016
Authors: Kang-Yu Peng; Matthew J Watt; Sander Rensen; Jan Willem Greve; Kevin Huynh; Kaushala S Jayawardana; Peter J Meikle; Ruth C R Meex Journal: J Lipid Res Date: 2018-07-24 Impact factor: 5.922
Authors: Mikiko Watanabe; Garima Singhal; Ffolliott M Fisher; Thomas C Beck; Donald A Morgan; Fabio Socciarelli; Marie L Mather; Renata Risi; Jared Bourke; Kamal Rahmouni; Owen P McGuinness; Jeffrey S Flier; Eleftheria Maratos-Flier Journal: Endocrine Date: 2019-11-14 Impact factor: 3.633
Authors: Ashley Patton; Tyler Church; Caroline Wilson; Jean Thuma; Douglas J Goetz; Darlene E Berryman; Edward O List; Frank Schwartz; Kelly D McCall Journal: J Endocrinol Date: 2018-04-17 Impact factor: 4.286
Authors: Marta Seghieri; Alexander S Christensen; Andreas Andersen; Anna Solini; Filip K Knop; Tina Vilsbøll Journal: Front Endocrinol (Lausanne) Date: 2018-11-06 Impact factor: 5.555